Edward Kim

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 6

Top Topics

Molecularly Imprinted

Bipolar Disorder

Top Venues

Neuropsychiatric disease and treatment

Schizophrenia (Heidelberg, Germany)

JMIR mental health

This page only lists publications with an associated author ORCID identifier.

Publications

Christoph U Correll, Amber Martin, Charmi Patel, Carmela Benson, Rebecca Goulding, Jennifer Kern-Sliwa, Kruti Joshi, Emma Schiller, Edward Kim
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia (Heidelberg, Germany) 8 (1) (2022)
Kim T Mueser, Eric D Achtyes, Jagadish Gogate, Branislav Mancevski, Edward Kim, H Lynn Starr
Telehealth-Based Psychoeducation for Caregivers: The Family Intervention in Recent-Onset Schizophrenia Treatment Study. JMIR mental health 9 (4) (2022)
Amy O'Donnell, Sanjai Rao, Ibrahim Turkoz, Srihari Gopal, Edward Kim
Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate. Neuropsychiatric disease and treatment 17 (2021)
Christoph U Correll, Edward Kim, Jennifer Kern Sliwa, Wayne Hamm, Srihari Gopal, Maju Mathews, Raja Venkatasubramanian, Stephen R Saklad
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS drugs 35 (1) (2021)
Maju Mathews, Srihari Gopal, Arun Singh, Isaac Nuamah, Katalin Pungor, Wilson Tan, Bernardo Soares, Edward Kim, Adam J Savitz
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies. Neuropsychiatric disease and treatment 16 (2020)
Srihari Gopal, Jagadish Gogate, Katalin Pungor, Edward Kim, Arun Singh, Maju Mathews
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study. Neuropsychiatric disease and treatment 16 (2020)